ReviewFrontiers in nuclear medicine2026
Quantification in bone SPECT/CT.
Review in Frontiers in nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Quantitative bone SPECT/CT enables objective assessment of skeletal radiotracer uptake using standardised uptake values (SUVs) and related parameters. Advances in reconstruction, correction methods, calibration and detector technology have improved measurement reliability and expanded interest in oncological and benign skeletal applications. This review evaluates current clinical applications, technical limitations and future directions of quantitative bone SPECT/CT. Methods: PubMed was searched for English-language full-text human studies published from January 2015 to March 2025 using a reproducible Boolean strategy focused on quantitative or semi-quantitative bone SPECT/CT. Screening followed PRISMA 2020 principles. Thirteen primary studies were included in the qualitative synthesis; reviews, case reports, guidelines, position papers and other supporting publications were used only for narrative context. Results: Quantitative bone SPECT/CT showed potential value for differentiating benign from malignant bone lesions, comparison with 18F-NaF PET/CT, longitudinal response assessment and prognostic evaluation before bone-targeted radionuclide therapy. Potential applications were also identified in condylar hyperplasia, fibrous dysplasia, vertebral compression fractures and degenerative joint disease. However, most studies were retrospective, single-centre and technically heterogeneous. Reported SUV thresholds were influenced by tumour type, lesion phenotype, uptake time, acquisition/reconstruction parameters, calibration, segmentation and recovery-coefficient methods, limiting transferability. Conclusions: Quantitative bone SPECT/CT is a promising technique for objective assessment of bone metabolism, but current evidence supports cautious use as an adjunct to morphology and clinical context. Prospective multicentre studies with harmonised protocols, risk-of-bias control and patient-relevant endpoints are required. Artificial intelligence, radiomics, advanced detectors and theranostics should currently be considered research opportunities rather than established applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.